NCT05681780 2025-12-04
Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Active not recruiting
H. Lee Moffitt Cancer Center and Research Institute
National Institutes of Health Clinical Center (CC)
Northwestern University
Cancer Research UK